Following a key announcement this past Friday it could well be a good time for investors to consider taking a look into the Umbra Applied Technologies Group Inc (OTCMKTS:UATG) stock this morning. The company announced that OssifixOrthopedics, its subsidiary company, had started a comparative study with physicians spread across as many as six cities.
On Friday, UATG stock gained 0.16% to $0.0085 with 2.19 million shares, compared to volume of 4.21 million shares. The stock moved within a range of $0.0075 – 0.0093 after opening trade at $0.0080.
UAT Group Subsidiary, Ossifix Orthopedics Begins Comparative Study
The comparative study in question would compare the materials and methods related to the available traditional treatments with The Ossifix Javelin allograft bone pin system. The initial studies revealed patients getting early ambulation and some of them even being able to drive the following day.
It revealed that patients were getting released in half the usual time. The study showed that the Javelin pin had managed to incorporate and become a part of the bone structure without any kind of ossification.
The patients who were part of the study had been released after four weeks and that was an improvement on the 8 to 10 weeks that is generally taken when treated with the traditional treatments and methods. The latest revelation from Umbra Applied Technologies with regards to the product from is subsidiary unit was an important one. It remains to be seen if it leads to any move on the stock or not.
Ossifix CEO, Mark Estrada, stated: “We are currently in the process of compiling and analyzing outcome data from surgical procedures done during the latter part of 2022. We will continue gathering data for the next few months and are expecting to compile data on approximately 120 patients in total. The study will report those outcomes from approximately 12 surgeons and compare the Javelin to competitive metallic product outcomes.”